

### REMARKS

Claims 1-7 and 10-13 and 15-31 are pending in the present application.

Claims 10-13 are currently withdrawn.

Claim 1 is amended to remove the group -NR<sup>8</sup>R<sup>9</sup>.

Claim 7 is amended to independent form.

#### Claim Rejections - 35 USC § 102

Claims 1-7 are rejected under 35 U.S.C. 102(e) as being anticipated by Sumioka et al. (US 2003/0072923).

Claim 1 has been amended to delete the group -NR<sup>8</sup>R<sup>9</sup> thereby rendering the rejection of claim 1 moot.

Claims 2-6 ultimately depend from claim 1 and are patentable over Sumioka et al. due to the amendment of claim 1.

The compounds listed in claim 7 are not recited in Sumioka et al. therefore the rejection is improper. More specifically, the compounds listed in Sumioka et al. have an additional -NR group between the carboxyl group and the remainder of the molecule.

The rejection of claims 1-7 under 35 U.S.C. 102(e) as being anticipated by Sumioka et al. is overcome by amendment and/or traversed.

#### New

Claims 15-31 are newly added claims which are believed to be patentable over the art of record. No new matter is entered by the amendment.


#### Withdrawn Claims

Claims 10-13 are currently withdrawn as being directed to a non-elected species. In the event that the rejection based on Sumioka et al. is withdrawn Applicants request a search and examination of claims 10-13 on the merits.

### CONCLUSIONS

Claims 1-7, 10-13 and 15-31 are pending in the present application. All claims are believed to be in condition for allowance. Notice thereof is respectfully requested.

Respectfully submitted,



Joseph T. Guy, Ph.D.  
Agent for Applicants  
Registration Number 35,172  
Customer No.: 46591

September 13, 2007